Pharmaceutical News

RSS

Targeted antibody therapy provides long-lasting relief from neuropathic pain

Pain is a natural protective mechanism that alerts the body to actual or potential injury. But when nerves themselves are damaged, they can generate abnormal pain signals even in the absence of a new injury.

16 Sep 2026

New treatment option approved in Japan for rare genetic liver disorders

A new indication for an existing drug has been approved in Japan to treat patients with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2, a group of rare genetic liver disorders.

15 Sep 2026

Add-on drug lumateperone boosts sexual function in patients with depression

Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received an add- on treatment with the drug lumateperone saw significantly improved sexual function, found a new study led by a University of Virginia School of Medicine researcher.

15 Sep 2026

US Medicare's new 'Most-Favored-Nation' pricing policy could raise international medicine prices

A new modeling study published in The Lancet suggests that US Medicare's new 'Most-Favored-Nation' pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push pharmaceutical manufacturers to raise prices or delay launches.

15 Sep 2026

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

In a US multicenter electronic health record study, researchers compared tirzepatide with semaglutide in adults with asthma and type 2 diabetes, matching 8,176 patients in each treatment group. Asthma exacerbation risk was similar between treatments, while tirzepatide was associated with a lower likelihood of receiving a short-acting beta-agonist prescription.

14 Sep 2026

Common medications trigger potentially harmful prescribing cascades in older adults

A new Ontario-wide study reveals that common medications, from statins to iron supplements, are quietly setting off prescribing cascades that leave older adults unknowingly taking drugs to treat side effects of other drugs.

10 Sep 2026

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.

10 Sep 2026

Shortages of crucial cancer medications continue to impact US healthcare

Today, the National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-published updated data on the current impact of generic cancer medication shortages in the United States.

10 Sep 2026

Tizanidine looked promising early in a migraine trial, but the benefit did not last

A randomized, double-blind, placebo-controlled trial found that low-dose tizanidine did not provide sustained reductions in headache burden over 12 weeks in people with episodic migraine, despite a transient improvement with the 1 mg dose at week 4. Exploratory analyses suggested that smoking and sex may influence tizanidine exposure, while sex-specific efficacy signals remained hypothesis-generating and require confirmation.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026

GLP-1 treatment linked to 40% fewer asthma attacks

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

Childhood obesity prescriptions for GLP-1 drugs surge in the U.S.

Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new study shows.

4 Sep 2026

GLP-1 drugs could reshape fashion and body culture

As GLP-1 medications change American bodies and attitudes about weight, a West Virginia University fashion expert says their influence could reach all the way from consumers' closets to designers' drawing boards and retailers' racks.

4 Sep 2026

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

Semaglutide extends lifespan and slows physiological aging in healthy mice

A National Institutes of Health (NIH)-funded study has shown that the GLP-1 drug semaglutide extended lifespan in older, healthy mice by tempering the detrimental effects of aging.

2 Sep 2026

Host-targeting drugs offer new way to fight flu resistance

A drug that targets the host rather than the virus could get around the problem of anti-viral resistance. Every year, hundreds of thousands of people die of seasonal influenza, caused by infection with influenza A and B viruses.

1 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Pharmaceutical News

Targeted antibody therapy provides long-lasting relief from neuropathic pain

New treatment option approved in Japan for rare genetic liver disorders

Add-on drug lumateperone boosts sexual function in patients with depression

US Medicare's new 'Most-Favored-Nation' pricing policy could raise international medicine prices

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

Common medications trigger potentially harmful prescribing cascades in older adults

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

Shortages of crucial cancer medications continue to impact US healthcare

Tizanidine looked promising early in a migraine trial, but the benefit did not last

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Digital companion apps help secure long-term habits during GLP-1 therapy

GLP-1 treatment linked to 40% fewer asthma attacks

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

Childhood obesity prescriptions for GLP-1 drugs surge in the U.S.

GLP-1 drugs could reshape fashion and body culture

Semaglutide extended lifespan in older female mice, but that was not the only finding

Semaglutide extends lifespan and slows physiological aging in healthy mice

Host-targeting drugs offer new way to fight flu resistance

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News